- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01355055
Sympathetic Activity and Renal Denervation (ReD)
May 16, 2011 updated by: Hannover Medical School
Influences of Catheter-based Renal Denervation on Central Sympathetic Nervous System Regulation in Refractory Hypertension
Primary hypothesis:
Catheter-based renal denervation reduces central sympathetic activation in patients with refractory hypertension.
Secondary hypotheses:
- The magnitude of the individual depressor response after catheter-based renal denervation depends on the extent of sympathoinhibition.
- Both, the reduction in arterial pressure and in central sympathetic activation are sustained over time up to 24±3 months after catheter-based renal denervation.
- Catheter-based renal denervation resets the sympathetic baroreflex to lower blood pressure values.
Study Overview
Status
Unknown
Conditions
Study Type
Observational
Enrollment (Anticipated)
26
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Heusser Karsten, MD
- Phone Number: +495115322723
- Email: heusser.karsten@mh-hannover.de
Study Locations
-
-
-
Hannover, Germany
- Recruiting
- Hannover Medical School
-
Principal Investigator:
- Karsten Heusser, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients with refractory hypertension, in whom catheter-based renal denervation is indicated and who are scheduled for this procedure, will be recruited from the outpatient clinic.
Description
Inclusion Criteria:
- Refractory hypertension (as defined by the WHO: poorly controlled hypertension (>140/90 mmHg) despite adequate doses of at least three antihypertensive drugs including a diuretic)
- Men or women aged >18 years
- Intact peroneal nerve
- Written informed consent
Exclusion Criteria:
- Diseases, dysfunctions, or medications (such as NET inhibitors) that exclude a participation in the study according to the investigator.
- Legal incompetence or circumstances that interfere with the patient´s ability to fully understand scope, relevance, and/or consequences of participation in this study.
- People in custody
- hypersensitivity to clonidine, phenylephrine, or nitroprusside-sodium
- sick sinus syndrome, second or third degree AV block, bradycardia < 50 bpm (contraindication for clonidine)
- endogenous depression (contraindication for clonidine)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2011
Study Registration Dates
First Submitted
May 16, 2011
First Submitted That Met QC Criteria
May 16, 2011
First Posted (Estimate)
May 17, 2011
Study Record Updates
Last Update Posted (Estimate)
May 17, 2011
Last Update Submitted That Met QC Criteria
May 16, 2011
Last Verified
March 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DE-MHH-ReD-EK5853
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland